Cellectis (CLLS) EBITDA Margin Growth (3y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -40,178.00 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 530.00 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -932.00 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 7,003.00 |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | 1.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.64 Mn |
| Dec 31, 2025 | -11,536.00 |
| Sep 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 203,243.00 |
| Mar 31, 2025 | 162,236.00 |
| Dec 31, 2024 | 2,252.00 |
| Sep 30, 2024 | 44,325.00 |
| Jun 30, 2024 | 12,186.00 |
| Mar 31, 2024 | -38,368.00 |
| Dec 31, 2023 | -1.02 Mn |
| Sep 30, 2023 | -1.29 Mn |
| Jun 30, 2023 | -1.21 Mn |
| Mar 31, 2023 | -1.69 Mn |
| Dec 31, 2022 | 84,924.00 |
| Sep 30, 2022 | -1.53 Mn |
| Jun 30, 2022 | 95,938.00 |
| Mar 31, 2022 | 47,613.00 |
| Dec 31, 2021 | 294,844.00 |
| Sep 30, 2021 | 268,057.00 |
| Jun 30, 2021 | 9,434.00 |
| Mar 31, 2021 | 33,453.00 |
| Dec 31, 2020 | 11,483.00 |
| Sep 30, 2020 | -5,520.00 |
| Jun 30, 2020 | -83,355.00 |
| Mar 31, 2020 | 32,200.00 |
| Dec 31, 2019 | -62,247.00 |
| Sep 30, 2019 | -19,954.00 |
| Jun 30, 2019 | -137,107.00 |
| Mar 31, 2019 | -193,909.00 |
| Dec 31, 2018 | -302,690.00 |
| Sep 30, 2018 | -301,335.00 |
| Jun 30, 2018 | -26,423.00 |
| Mar 31, 2018 | -37,007.00 |